2024-11-05T08:50:14-06:00 2024-06-30 541498950 RENNER AND COMPANY CPA PC 700 NORTH FAIRFAX STREET SUITE 400 ALEXANDRIA VA 22314 990 2023-07-01 112779073 SJOGREN'S FOUNDATION INC SJOG 3015304420 10701 PARKRIDGE BLVD 170 RESTON VA 20191 JANET CHURCH CHIEF EXECUTIVE OFFICER 3015304420 2024-11-04 1 1 ANDREW E YOUNG CPA P01203950 7035351200 2024-11-04 2023 2024-10-15 13:58:12Z JANET CHURCH 10701 PARKRIDGE BLVD 170 RESTON VA 20191 4694838 0 X WWW.SJOGRENS.ORG X 1983 NY SEE SCHEDULE O FOR DESCRIPTION OF ORGANIZATION'S PRIMARY MISSION. 17 17 19 656 0 0 2756148 2964863 489669 442631 44371 90511 34525 -339 3324713 3497666 275678 390313 0 0 1657790 1699790 0 0 232968 908378 1084309 2841846 3174412 482867 323254 3694277 4167805 1128554 1255608 2565723 2912197 X THE FOUNDATION'S MISSION IS TO PROVIDE EDUCATION AND RESOURCES TO SJOGREN'S PATIENTS AND THEIR LOVED ONES, PROVIDE CREDIBLE RESOURCES/EDUCATION TO HEALTHCARE PROFESSIONALS, SERVE AS THE VOICE OF ALL PATIENTS THROUGH ADVOCACY AND FUND INNOVATIVE RESEARCH. 0 0 955672 390313 THE SJOGREN'S FOUNDATION AWARDED FOUR RESEARCH GRANTS UNDER THE ANNUAL SJOGREN'S FOUNDATION GRANT PROGRAM TO UNIVERSITY AFFILIATED RESEARCHERS IN MAY 2024. THREE PILOT GRANTS WERE AWARDED AND ONE HIGH IMPACT GRANT AWARDED. THE SJOGREN'S FOUNDATION ALSO AWARDED A DYNAMIC GRANT TO THE UNIVERSITY OF PENNSYLVANIA FOR DEVELOPMENT OF CORE OUTCOMES SET OF DOMAINS FOR SJOGREN'S DISEASE. THE FOUNDATION PAID THE SECOND PAYMENT TO SUPPORT THE FNIH AMP AIM RESEARCH PROJECT ON SJOGREN'S AND AUTOIMMUNE DISEASE, AND THE SECOND PAYMENT OF THE OKLAHOMA MEDICAL RESEARCH FOUNDATION GRANT FOR THE GENOME RESEARCH PROJECT.THE SJOGREN'S FOUNDATION ALSO WORKED CLOSELY WITH MULTIPLE PHARMA COMPANIES TO PREPARE FOR, AND BRING, PHASE 2 AND PHASE 3 MOVED CLINICAL TRIALS FORWARD. THE FOUNDATION SUPPORTED THESE PROGRAMS BY CONFERRING WITH PHARMA ON PROTOCOLS AND PATIENT NEEDS, CERTIFYING CLINICAL TRIAL INVESTIGATORS ON PROPER USE OF ESSDAI OUTCOME MEASURES, AND ENGAGED PATIENTS TO ENCOURAGE TRIAL ENROLLMENT, IN ORDER TO HELP BRING THERAPIES TO MARKET. 236496 846 NEWSLETTER - THE FOUNDATION PRODUCES TWO NEWSLETTERS. "CONQUERING SJOGREN'S" IS A PATIENT FOCUSED NEWSLETTER WITH INFORMATION ABOUT SJOGREN'S AND ITS MANY MANIFESTATIONS. CS IS PRODUCED BI-MONTHLY. THE "SJOGREN'S QUARTERLY" IS A PROFESSIONAL PUBLICATION PRODUCED 4 TIMES A YEAR AND OFFERED FREE TO ALL HEALTHCARE PROFESSIONALS TO INCREASE AWARENESS AND EDUCATION AROUND SJOGREN'S. 881830 THE SJOGREN'S FOUNDATION INCREASED PATIENT SUPPORT AND EDUCATION PROGRAMS IN 2024 AS WELL AS HEALTHCARE PROVIDER EDUCATION AND AWARENESS ABOUT SJOGREN'S AND THE SYSTEMIC, MULTI-FACETED NATURE OF THE DISEASE. OF NOTE WAS THE EXPANSION OF PROVIDER OUTREACH AND CME PROGRAMS FOR SPECIALTIES AND PRIMARY CARE PROVIDERS. IN APRIL 2024, THE FOUNDATION'S WORK TO CHANGE THE DISEASE NAME FROM SJOGREN'S SYNDROME TO SJOGREN'S DISEASE WAS INTERNATIONALLY ADOPTED BY CLINICIANS AND PATIENTS. THIS NOMENCLATURE BETTER REFLECTS CURRENT RESEARCH AND INFORMATION ABOUT THE DISEASE AS WELL AS THE LIVED EXPERIENCE BY PATIENTS. THE FOUNDATION ALSO INCREASED OUR ADVOCACY EFFORTS WITH CENTERS FOR MEDICARE AND MEDICAID AND CONGRESS TO RAISE AWARENESS ABOUT SJOGREN'S. WE SUCCEEDED IN GETTING HOUSE RESOLUTION #1094 PRESENTED IN CONGRESS TO AFFIRM APRIL AS SJOGREN'S AWARENESS MONTH WHICH INCLUDED UPDATED NAME OF THE DISEASE AND CORRECT INFORMATION ABOUT THE SYSTEMIC NATURE OF THE DISEASE AND NEED FOR INCREASED RESEARCH FUNDING. WE CONTINUED TO ADVANCE OUR RELATIONSHIPS WITH CLINICIANS, RESEARCHERS, GOVERNMENT SCIENTISTS, AND CORPORATE SCIENTISTS WHO ARE INTERESTED IN SJOGREN'S. 695199 409922 OTHER PROGRAMS WITHIN THE FOUNDATION INCLUDE STRATEGIC GOVERNANCE PROJECTS, CONFERENCES AND MEETINGS RELATED TO TOPICS RELEVANT TO THOSE WITH SJOGREN'S, AS WELL AS VARIOUS INDUSTRY AND MEMBERSHIP PROJECTS AND SERVICES FOR THOSE WITH SJOGREN'S OR ENTITIES PROVIDING SUPPORT TO THOSE INDIVIDUALS. 695199 409922 2769197 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 11 0 19 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA CO FL MD MS OH OR SC TN VA WA X X SJOGREN'S FOUNDATION 3015304420 10701 PARKRIDGE BLVD SUITE 170 RESTON VA 20191 SUSAN BARAJAS CHAIRMAN 2.00 X X 0 0 0 DONALD E THOMAS MD PAST CHAIRMAN 2.00 X X 0 0 0 VIDYA SANKAR DMD MHS TREASURER 2.00 X X 0 0 0 KATIE FORTE SECRETARY 2.00 X X 0 0 0 ALAN BAER MD DIRECTOR, CHAIRMAN OF MSAC 2.00 X 0 0 0 ALLISSA LATHAM DIRECTOR 2.00 X 0 0 0 BRENT P GOODMAN MD DIRECTOR 2.00 X 0 0 0 DANIEL WALLACE MD DIRECTOR 2.00 X 0 0 0 DAVID SCHRADER DIRECTOR 2.00 X 0 0 0 JONATHAN MORSE MSC DIRECTOR 2.00 X 0 0 0 NISHANT GUPTA MD DIRECTOR 2.00 X 0 0 0 ROBYN LAUKIEN DIRECTOR 2.00 X 0 0 0 SARA MCCOY MD DIRECTOR 2.00 X 0 0 0 SCOTT LIEBERMAN MD DIRECTOR 2.00 X 0 0 0 TAMMY DOTSON DIRECTOR 2.00 X 0 0 0 TOM IATESTA DIRECTOR 2.00 X 0 0 0 VATINEE BUNYA MD MSCE DIRECTOR 2.00 X 0 0 0 JANET CHURCH PRESIDENT AND CEO 40.00 X 384450 0 23911 KATHERINE MORLAND HAMMITT VP OF MEDICAL AND SCIENTIFIC AFFAIRS 40.00 X 179450 0 6150 BEN BASLOE VP OF PHILANTHROPY AND OPERATIONS 40.00 X 127283 0 20924 LANE DESTRO DIR OF CORPORATE RELATIONS AND INITIATIVES 40.00 X 115034 0 8737 MICHELE CHAMPIGNY VP OF PATIENT SERVICES AND EDUCATION 40.00 X 108863 0 3016 MATTHEW MAKARA SR. DIR OF RESEARCH AND SCIENTIFIC AFFAIRS 40.00 X 108211 0 8157 1023291 0 70895 6 0 1 0 0 288711 2676152 36192 2964863 MEMBERSHIP DUES 541900 254353 254353 CONFERENCE 541900 187432 104682 82750 NEWSLETTER 541900 846 846 442631 89055 89055 5314 5314 1131343 1129887 1456 1456 1456 0 288711 56540 -56540 -56540 24738 10745 13993 13993 MISCELLANEOUS INCOME 541900 36894 36894 36894 3497666 410768 0 122035 390313 390313 593961 511875 36410 45676 881165 759389 54015 67761 125537 108189 7695 9653 99127 85428 6076 7623 5054 5054 32747 32747 7898 7898 68285 62860 2406 3019 23866 20568 1463 1835 90050 77606 5519 6925 43581 43581 2246 2246 42834 36911 2629 3294 14563 12551 892 1120 AWARENESS ACTIVITIES 287953 287953 0 0 MISCELLANEOUS 113308 108577 474 4257 PRINTING, DUPLICATING, 112420 88771 363 23286 POSTAGE AND DELIVERY 66962 54585 452 11925 172542 120040 5908 46594 3174412 2769197 172247 232968 226724 697030 469995 220026 13473 223294 13185 17109 18879 20159 262407 212415 77324 49992 2657226 2833654 23126 9911 194345 96630 3694277 4167805 92492 66425 350150 475000 394017 561934 291895 152249 1128554 1255608 X 1564827 1911301 1000896 1000896 2565723 2912197 3694277 4167805 323254 23220 0 X X 0 1 X 1 0 X 2004952 2505185 2391109 2756148 2964863 12622257 357683 368639 434297 425594 384619 1970832 2362635 2873824 2825406 3181742 3349482 14593089 1361236 791081 742203 960014 1050899 4905433 0 1361236 791081 742203 960014 1050899 4905433 9687656 30736 20326 27789 22161 94369 195381 30736 20326 27789 22161 94369 195381 1798 12486 6768 37718 36894 95664 2395169 2906636 2859963 3241621 3480745 14884134 0.65090 0.57030 0.01310 0.00850 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1000896 1000896 1000896 1000896 1000896 1000896 1000896 1000896 1072896 72000 1000896 1.00000 0 0 166103 145513 20590 96304 66902 29402 49992 LEASE LIABILITY 152249 152249 X 3523733 23220 23220 3500513 7898 -10745 -2847 3497666 3177259 10745 10745 3166514 7898 7898 3174412 PART V, LINE 4: THE FOUNDATION'S ENDOWMENT FUNDS CONSIST OF A BEQUEST THAT WAS RESTRICTED FOR THE PURPOSES OF RESEARCH. PART X, LINE 2: IN ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, ACCOUNTING STANDARDS REQUIRE AN ENTITY TO RECOGNIZE THE FINANCIAL STATEMENT IMPACT OF A TAX POSITION WHEN IT IS MORE-LIKELY-THAN-NOT THAT THE POSITION WILL NOT BE SUSTAINED UPON EXAMINATION. MANAGEMENT EVALUATED THE FOUNDATION'S TAX POSITIONS AND CONCLUDED THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THIS GUIDANCE. PART XI, LINE 4B - OTHER ADJUSTMENTS: RECLASSIFICATION OF COSTS OF GOODS SOLD -10,745. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASSIFICATION OF COSTS OF GOODS SOLD 10,745. WALKS AND SIPS EVENTS 288521 288521 56540 PARTNER PROGRAMS 190 190 288711 288711 56540 56540 -56540 1 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 7408 BOELTER HALL BOX 951600 LOS ANGELES CA 90095 956006143 SECTION 501(C)(3) 50000 0 FMV N/A RESEARCH GRANT OKLAHOMA MEDICAL RESEARCH FOUNDATION 825 NE 13TH STREET OKLAHOMA CITY OK 73104 730580274 SECTION 501(C)(3) 200000 0 FMV N/A RESEARCH GRANT NORTHEASTERN UNIVERSITY 360 HUNTINGTON AVENUE BOSTON MA 02115 041679980 SECTION 501(C)(3) 50000 0 FMV N/A RESEARCH GRANT NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIA 31 CENTER DRIVE BETHESDA MD 20892 520858115 FEDERAL GOVERNMENT 50000 0 FMV N/A RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3900 WALNUT ST PHILADELPHIA PA 19104 231352685 SECTION 501(C)(3) 25000 0 FMV N/A RESEARCH GRANT 5 0 PART I, LINE 2: THE SJOGREN'S FOUNDATION ENCOURAGES AND SUPPORTS RESEARCH INTO SJOGREN'S BY OFFERING ANNUAL RESEARCH GRANTS. THERE ARE TWO ANNUAL AWARDS: A HIGH IMPACT GRANT AND A PILOT GRANT. THE FOUNDATION ADDED TWO NEW RESEARCH GRANT POLICIES CALLED DYNAMIC GRANT POLICY AND PARTNER GRANT POLICY, TO ENCOURAGE ADDITIONAL PROPOSALS THAT FALL OUTSIDE OF THE SCOPE OF OUR ANNUAL GRANTS. ALL GRANT OPPORTUNITIES ARE OPEN TO APPLICANTS AT U.S. INSTITUTIONS. GRANTS ARE AWARDED BY A PEER REVIEW PANEL OF SJOGREN'S RESEARCH PROFESSIONALS AND GRANTEES ARE REGULARLY REVIEWED THROUGHOUT THE GRANT CYCLE. OUR RESEARCH PROGRAM PROMOTES BASIC SCIENCE AND CLINICAL INVESTIGATIONS INTO THE CAUSE, PREVENTION, DIAGNOSIS, TREATMENT AND ULTIMATELY A CURE FOR THIS PREVALENT AUTOIMMUNE DISEASE. X X X X X 0 0 0 0 0 0 0 0 0 JANET CHURCH PRESIDENT AND CEO 309450 0 75000 0 0 0 9375 0 14536 0 408361 0 0 0 KATHERINE MORLAND HAMMITT VP OF MEDICAL AND SCIENTIFIC AFFAIRS 169450 0 10000 0 0 0 5175 0 975 0 185600 0 0 0 X 4 36192 FMV 0 1 0 FORM 990, PART I, LINE 1 THE FOUNDATION'S MISSION IS TO PROVIDE EDUCATION AND RESOURCES TO SJOGREN'S PATIENTS AND THEIR LOVED ONES, PROVIDE CREDIBLE RESOURCES/EDUCATION TO HEALTHCARE PROFESSIONALS, SERVE AS THE VOICE OF ALL PATIENTS THROUGH ADVOCACY AND FUND INNOVATIVE RESEARCH. FORM 990, PART VI, SECTION B, LINE 11B BOARD MEMBERS WILL HAVE A WEEK TO REVIEW 990 AND MAKE COMMENTS BEFORE IT IS FILED. THE 990 WILL BE READ BY THE CHIEF EXECUTIVE OFFICER BEFORE IT IS SIGNED. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR, OFFICER, COMMITTEE MEMBER OR EMPLOYEE MUST ANNUALLY REVIEW A COPY OF THIS POLICY AND SHALL BE REMINDED OF THE OBLIGATION TO CONFORM TO IT. EACH COVERED PERSON MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST INFORMATION FORM IDENTIFYING ANY RELATIONSHIPS, POSITIONS OR CIRCUMSTANCES IN WHICH THE COVERED PERSON IS INVOLVED THAT HE OR SHE BELIEVES COULD CREATE A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15A BOARD ANNUALLY REVIEWS COMPARABLE SALARY AND BONUS INFORMATION AND COMPARES CEO SALARY. FORM 990, PART VI, SECTION C, LINE 19 FINANCIALS ARE POSTED ON THE FOUNDATION'S WEBSITE FOR DONORS, PATIENTS AND VISITORS TO REVIEW. GOVERNANCE DOCUMENTS, CONFLICT OF INTEREST, ETC. ARE ALL AVAILABLE BY CONTACTING THE MAIN OFFICE, FREE OF CHARGE. ALSO THE COPIES OF OUR 990S AND FINANCIALS ARE AVAILABLE BY CONTACTING THE MAIN OFFICE. FORM 990, PART XII, LINE 2C THE FOUNDATION HAS NOT CHANGED THIS PROCESS FROM THE PRIOR YEAR. THE BOARD OF DIRECTORS IS RESPONSIBLE FOR OVERSIGHT OVER THE INDEPENDENT AUDIT AND SELECTION OF THE INDEPENDENT AUDITORS.